Nicholas Laccona - Dec 9, 2022 Form 4 Insider Report for Bellerophon Therapeutics, Inc. (BLPH)

Role
FINANCIAL OFFICER, (PFO & PAO)
Signature
/s/ Nicholas Laccona
Stock symbol
BLPH
Transactions as of
Dec 9, 2022
Transactions value $
-$5,143
Form type
4
Date filed
12/13/2022, 04:25 PM
Previous filing
Jan 28, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLPH Common Stock Options Exercise +18K 18K Dec 9, 2022 Direct F1
transaction BLPH Common Stock Tax liability -$5.14K -5.53K -30.72% $0.93 12.5K Dec 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLPH Restricted Stock Units Options Exercise $0 -18K -50% $0.00 18K Dec 9, 2022 Common Stock 18K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Bellerophon common stock.
F2 On January 26, 2022, the reporting person was granted 36,000 restricted stock units, 50% vesting on December 9, 2022 and 50% vesting on December 8, 2023, as long as the reporting person remains in the service of Bellerophon through the respective vesting date.